Pylarify was the largest of Lantheus Holdings, Inc.’s 7 reported lines in fiscal 2025, at $989.12M — 39% of $2.53B.
| Product and Service | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pylarify | $527.41M | $851.30M | $1.06B | $989.12M | |||||||||
| Total Radiopharmaceutical Oncology | — | — | — | $989.12M | |||||||||
| Definity | $244.99M | $279.77M | $317.79M | $330.25M | |||||||||
| D E F I N I T Y | — | — | — | — | |||||||||
| Technelite | $88.86M | $87.37M | $95.49M | $86.80M | |||||||||
| Techne Lite | — | — | — | — | |||||||||
| Other Nuclear | — | — | — | — | |||||||||
| Other | — | — | — | — | |||||||||
| Other Products | — | — | — | — | |||||||||
| Product Revenue, Net | — | — | — | — | |||||||||
| Neuraceq | — | — | — | $51.45M | |||||||||
| Xenon | — | — | — | — | |||||||||
| Strategic Partnerships & Other Revenue | $46.87M | $51.88M | $38.18M | $59.38M | |||||||||
| Other Precision Diagnostics | $22.83M | $22.98M | $24.23M | $24.62M | |||||||||
| Other Radiopharmaceutical Oncology | $4.10M | $3.13M | $384.00K | — | |||||||||
| License & Royalty Revenues | — | — | $9.13M | — | |||||||||
| Rebates & Allowances | — | — | — | — | |||||||||
| Total | $935.06M | $1.30B | $1.54B | $2.53B |
In fiscal 2025, which ended December 31, 2025, the 7 revenue lines Lantheus Holdings, Inc. reported in this breakdown added up to $2.53B. The revenue lines reported changed from fiscal 2024, so the total is not directly comparable with the $1.54B reported that year. Pylarify was the largest revenue line, at $989.12M or 39.1% of the total, followed by Total Radiopharmaceutical Oncology ($989.12M, 39.1%) and Definity ($330.25M, 13.0%). Together, the two largest revenue lines made up 78.2% of this total.
Compared with fiscal 2024, Strategic Partnerships & Other Revenue grew the fastest, rising 55.5% to $59.38M. Technelite fell the most, down 9.1% to $86.80M. Because revenue lines were added or dropped between the two years, part of this reflects how Lantheus Holdings, Inc. regrouped its reporting.
Neuraceq was first reported as a separate revenue line in fiscal 2025. The table also keeps 10 revenue lines that Lantheus Holdings, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 10 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2013 to 2025, as reported in Lantheus Holdings, Inc.'s annual filings.
United States was the largest of Lantheus Holdings, Inc.’s 2 reported lines in fiscal 2025, at $1.46B — 95% of $1.54B.
| Geography | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| United States | $1.26B | $1.48B | $1.46B | ||||||
| U.S | — | — | — | ||||||
| Rest Of World | $34.28M | $49.22M | $82.73M | ||||||
| All Other | — | — | — | ||||||
| Canada | — | — | — | ||||||
| Total | $1.30B | $1.53B | $1.54B |
In fiscal 2025, which ended December 31, 2025, the 2 regions Lantheus Holdings, Inc. reported in this breakdown added up to $1.54B. That is less than the $2.53B in its breakdown by revenue line, so these regions do not account for all of its revenue that year. United States was the largest region, at $1.46B or 94.6% of the total, followed by Rest Of World ($82.73M, 5.4%).
Compared with fiscal 2024, Rest Of World grew the fastest, rising 68.1% to $82.73M. United States fell the most, down 1.7% to $1.46B.
The table also keeps 3 regions that Lantheus Holdings, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers 9 fiscal years between 2013 and 2025, as reported in Lantheus Holdings, Inc.'s annual filings.
U.S was the largest of Lantheus Holdings, Inc.’s 2 reported lines in fiscal 2018, at $178.44M — 78% of $228.61M.
| Segment | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|---|---|---|
| U.S | $235.82M | $257.42M | $54.82M | $178.44M | ||
| Worldwide | — | — | $157.27M | — | ||
| International | $57.64M | $44.43M | $41.38M | $50.17M | ||
| Total | $293.46M | $301.85M | $253.47M | $228.61M |
In fiscal 2018, which ended December 31, 2018, the 2 segments Lantheus Holdings, Inc. reported in this breakdown added up to $228.61M. The segments reported changed from fiscal 2017, so the total is not directly comparable with the $253.47M reported that year. U.S was the largest segment, at $178.44M or 78.1% of the total, followed by International ($50.17M, 21.9%).
Compared with fiscal 2017, U.S grew the fastest, rising 225.5% to $178.44M. Because segments were added or dropped between the two years, part of this reflects how Lantheus Holdings, Inc. regrouped its reporting. Over fiscal 2015 to 2018, revenue across these segments went from $293.46M to $228.61M, a compound annual decline of 8.0%. U.S's share of the total fell from 80.4% to 78.1% over the same years.
The table also keeps 1 segment that Lantheus Holdings, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2013 to 2018, as reported in Lantheus Holdings, Inc.'s annual filings.
Lantheus Holdings, Inc. (LNTH) breaks its revenue down by revenue line, region and segment. In fiscal 2025, its largest revenue line was Pylarify, with $989.12M or 39.1% of the total, followed by Total Radiopharmaceutical Oncology at $989.12M (39.1%).
Pylarify was Lantheus Holdings, Inc.'s largest revenue line in fiscal 2025, with $989.12M in revenue, 39.1% of the $2.53B reported across its 7 revenue lines.
United States was Lantheus Holdings, Inc.'s largest region in fiscal 2025, with $1.46B in revenue, 94.6% of the $1.54B reported across its 2 regions.
U.S was Lantheus Holdings, Inc.'s largest segment in fiscal 2018, with $178.44M in revenue, 78.1% of the $228.61M reported across its 2 segments.
Of the Lantheus Holdings, Inc. regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Rest Of World grew the fastest, rising 68.1% from $49.22M to $82.73M.
Every figure is taken from Lantheus Holdings, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2013 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.